Company intelligence / Profile preview

Orbis Medicines

Ownership: Private
Development stage: Preclinical

Overview

Orbis Medicines is pioneering a new era in oral macrocycle drug discovery. Its proprietary nGen platform systematically generates and screens vast numbers of macrocyclic compounds ("nCycles") optimized for oral delivery. The company has raised significant funding to advance its preclinical pipeline focused on providing oral alternatives to existing injectable biologics, aiming at both established and previously undruggable targets. Proof-of-concept data have been published in leading scientific journals. No clinical results have been reported as of May 2025.

Therapeutic areas: Immunology
Modalities: Macrocycles (specifically, orally bioavailable macrocycles called "nCycles")
Industry: Biotech

Partnerships

Vivtex – research collaboration & exclusive licensing option for GI permeability screening technology to support development of orally dosable nCyclesInvestors/strategic relationships with Novo Holdings, Forbion, NEA, Lilly Ventures among others—these may also represent strategic partnerships given their industry stature.

Beyond the preview

Go deeper on Orbis Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbis Medicines.

Explore the full profile